Photo of Groundbreaking: New Jersey LT Governor Kim Guadagno joins members of the Teligent Management Team and Buena Vista Mayor as the company marks progress on the facility expansion in Buena, NJ. Credit: Dave Griffin.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, recently held the formal groundbreaking ceremony for the ongoing expansion of its manufacturing and research and development complex in Buena, NJ. The $45-50 million project will increase the facility’s footprint by more than 75,000 square feet, a 200 percent increase to current operations. Once completed, the expansion will include the installation of a new isolator-based sterile injectable manufacturing suite and will deliver a significant increase to the company’s manufacturing capacity for topical pharmaceutical products.
”We are making very good progress on our expansion, and this ceremony was an opportunity to celebrate what we are building together,” commented Teligent’s President and Chief Executive Officer, Jason Grenfell-Gardner. ”We continue to be on track for project completion by the end of 2017.”
The Lieutenant Governor of New Jersey, Kim Guadagno, and officials from state, county and local government offices also participated in the groundbreaking event.
”This is a proud moment for Teligent and Buena Vista Township, and it is the start of bigger and better times to come,” said Mayor Chuck Chiarello, on behalf of the Township Committee that was in attendance at the event.
As part of the event, the company also published the results of an economic impact study of the expansion recently conducted by Richard Perniciaro, Ph.D., Center for Regional & Business Research at Atlantic Cape Community College. The analysis determined that the construction phase of the project will provide $78 million in new economic activity to the Southern New Jersey region. In addition, Teligent expects to increase the number of employees at the facility by nearly 70%, to almost 200, after the expansion is complete. The complete economic impact study can be found here.
”This plant expansion reflects the reality that you can never stand still in our industry,” concluded Grenfell-Gardner. ”More importantly, it represents the vision and courage that all of our employees have to build a stronger, more capable, and more resilient organization for the future.”
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
